职称：教授
学历：博士
E-mail：zhuhaichuan@hbut.edu.cn
研究方向：血液肿瘤与细胞治疗
个人简介：
祝海川，湖北工业大学教授，硕/博士生导师。主要研究方向为血液肿瘤的形成、维持机制及CAR-T肿瘤免疫治疗新技术的开发及产业化。主持国自然面上基金、国自然青年科学基金C类等基金。担任Journal of Translational Internal Medicine和Cancer Innovation等期刊青年编委。截至目前以通讯作者（含共同）发表包括Cell metabolism, Nature Cancer, Cell research, Journal of Hematology & Oncology, Molecular therapy等论文40余篇，总引用超2000次，授权专利10项，参与完成产业转化项目3项。
教育及工作经历：
2025.07-至今 湖北工业大学 生命科学与健康工程学院 教授博士生导师
2019.07-2025.06武汉科技大学 生命科学与健康学院 博士后、副教授
2014.09-2019.07北京大学前沿交叉研究院整合生物学 博士
2010.09-2013.07湖北大学生命科学学院 生物化学硕士
近五年主要获奖：
1. 第十四届“挑战杯”中国大学生创业计划竞赛，国家金奖，1/4，2024
2. 第十三届“挑战杯”中国大学生创业计划竞赛，国家银奖，1/4，2023
3. 中国国际大学生创新大赛，全国铜奖，1/4，2024
主要研究论文：
1.Jiangzhou Shi#, Zijian Zhang#, Hong Cen#, Han Wu, Shangkun Zhang, Jiaxing Liu, Yingqi Leng, Anqi Ren, Xiyu Liu, Zhijie Zhang, Xiqin Tong, Jinjue Liang, Zhe Li, Fuling Zhou, Liang Huang, You Qin, Kunyu Yang, Tongcun Zhang*,Haichuan Zhu*. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.Journal of Hematology & Oncology. 2021.14, 162.
2.Zijian Zhang，Qifang Wu，Anqi Ren，Qian Chen，Jiangzhou Shi，Jiapeng Li，Xiyu Liu，Zhijie Zhang，Yuzhe Tang，Yuan Zhao，Ningning Yao，Xiaoyu Zhang，Changpeng Liu，Ge Dong，Jiaxuan Zhao，Meijun Xu，Yunqiang Yue，Jia Hu，Fan Sun，Yu Liu，Qilin Ao，Fuling Zhou，Hong Wu，Tongcun Zhang*，Haichuan Zhu*.ATF4 renders human T-cell acute lymphoblastic leukemia cell resistance to FGFR1 inhibitors through amino acid metabolic reprogramming. Acta Pharmacologica Sinica.2023.1-14.
3.Long Chen#, Anqi Ren#, Hangyu Chen, Qifang Wu, Yuan Zhao, Zijian zhang, Tongcun Zhang, Wu Zhong*, Jian Lin*, Haichuan Zhu*, Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL. Journal of Hematology & Oncology. 2023.16(1):113.
4.Yishuang Sun#, Zijian Zhang#, Haiou Li#, Xia Bu#, Li Chen#, Xiyong Wang, Lijun，Kong, Panpan Dai, Wenjing Song, Xiangling Xiao, Jie Shi, Bolin Xiang, Chuan He.GYingmeng Yao, Wenjun Xiong, Haisheng Yu, Congqing Jiang, Hudan Liu, Sufang Tian, Guoliang Qing, Zhiyong Yang, Wenyi Wei*, Gordon J. Freeman*, Haichuan Zhu*, Jinfang Zhang*. Destruction of VISTA by TRlM25 ablation in T cells potentiates cancer immunotherapy. Cell research. 2025.1-18.
5.Yifeng Xiao, Yanling Zhang, Zihao Zhao, Zijian Zhang, Xiaohui Zhang, Pengju Chen, Jin Gu*, Haichuan Zhu*, Peng Jiang*, Jie Cheng*. Aging microenvironment induces CD8+ T cell exhaustion by suppressing hepatic β-hydroxybutyrylate synthesis, Cell Metabolism, 2026. doi:10.1016/j.cmet.2026.08.009.
6.Jie Cheng#,Yifeng Xiao#, Ting Peng#, Zijian Zhang#, You Qin#, Yuqian Wang, Jiangzhou Shi, Jinxin Yan, Zihao Zhao, Liangtao Zheng, Zhijun He , Jianwei Wang, Zemin Zhang*, Cheng Li*, Haichuan Zhu*, Peng Jiang*. (2025). ETV7 limits the antiviral and antitumor efficacy of CD8+ T cells by diverting their fate toward exhaustion. Nature Cancer, 1-19.
7.Jie Chen#, Jinxin Yan#,Ying Liu#, Jiangzhou Shi#, Haoyu Wang, Hanyang Zhou, Yinglin Zhou,Tongcun Zhang,Lina Zhao, Xianbin Meng, Haipeng Gong, Xinxiang Zhang*, Haichuan Zhu*, Peng Jiang*. Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment, Cell Metabolism. 2023.35,1-18.
8.Jie Shi#, Zijian Zhang#, Hsin-Yi Chen#, Yingmeng Yao, Shanwen Ke, Kechun Yu, Jiangzhou Shi, Xiangling Xiao, Chuan He, Bolin Xiang, Yishuang Sun, Minling Gao, Xixin Xing, Haisheng Yu, Xiyong Wang,Wei-Chien Yuan,Bugi Ratno Budiarto, ShihYu Chen, Tongcun Zhang, YRu Lee*, Haichuan Zhu*, Jinfang Zhang*. Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR T cell therapy. Molecular Therapy. 2025.
9.Haichuan Zhu, Liuzhen Zhang, Yilin Wu, Bingjie Dong, Weilong Guo, Mei Wang, Lu Yang, Xiaoying Fan, Yuliang Tang, Ningshu Liu, Xiaoguang Lei, Hong Wu*, T-ALL leukemia stem cell'stemness' is epigenetically controlled by the master regulator SPI1. Elife. 2018;7: e38314.
